论文部分内容阅读
以安定为代表的苯并二氮杂(艹卓)类药物(BZs)的使用认为是对抑郁症治疗的一大进步。可是,这类药物所引起的依赖性则是它的严重缺点。BZs似乎作用于专一的BZ受体部位,经过很多尝试才找到了具有相似中枢活性,没有BZ的依赖性和其他副作用的抗郁化合物。卡它唑酯(Cartazolate)的研究给人们预示了可能的开发途径。后来注意力又转向了某些吡唑喹啉类化合物(pyrazolquinolines).最近,一个代号为CGS60625的新的吡唑吡啶衍生物引起了人们的注意。Williams等对该化合物即2-(4-甲氧苯基)2,3,5,6,7,8,9,10-八氢-环庚吡唑并[3,4-d]吡啶-3-酮进行
The use of benzodiazepines (BZs), represented by diazepam, is considered a significant improvement in the treatment of depression. However, the dependence caused by such drugs is its serious drawback. BZs appear to act on specific BZ receptor sites and after many attempts to find anti-depressant compounds with similar central activity, no BZ dependence, and other side effects. The study of Cartazolate has given people a preview of possible ways of development. Later, attention turned to certain pyrazolquinolines, and recently a new pyrazolopyridine derivative, code-named CGS60625, attracted much attention. Williams et al., The compound, 2- (4-methoxyphenyl) 2,3,5,6,7,8,9,10-octahydro-cycloheptapyrazolo [3,4- d] -one